Twist Bioscience Corporation

TWST · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▼ 0.0% below current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.0%

Institutions118.6%

Public / Other

Income Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	$376.57M	$312.97M	$245.11M	$203.56M	$132.33M	$90.10M	$54.38M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$185.57M	$179.63M	$155.38M	$119.33M	$80.62M	$61.41M	$47.43M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$136.26M	-$220.83M	-$217.16M	-$234.78M	-$152.73M	-$140.08M	-$108.85M
Operating income as a percentage of revenue.	-36.2%	-70.6%	-88.6%	-115.3%	-115.4%	-155.5%	-200.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$77.67M	-$208.73M	-$204.62M	-$217.86M	-$152.10M	-$139.93M	-$107.67M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.30	$-3.60	$-3.60	$-4.04	$-3.15	$-3.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.30	$-3.60	$-3.60	$-4.04	–	–	–

Balance Sheet

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$183.05M	$226.32M	$286.47M	$378.69M	$465.83M	$93.67M	$46.73M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$641.86M	$614.32M	$776.40M	$961.38M	$702.10M	$398.88M	$186.99M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	$0	$1.55M	$4.74M	$7.73M
Everything the company owes — debt, unpaid bills, and other obligations.	$168.90M	$141.63M	$152.97M	$171.99M	$121.28M	$62.62M	$34.91M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$472.96M	$472.69M	$623.43M	$789.38M	$580.82M	$336.26M	$152.08M

Cash Flow Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$47.63M	-$64.09M	-$142.47M	-$124.39M	-$112.24M	-$142.25M	-$87.94M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$28.00M	$5.08M	$27.78M	$101.86M	$27.06M	$9.87M	$14.76M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$75.63M	-$69.17M	-$170.25M	-$226.24M	-$139.31M	-$152.12M	-$102.69M

	You	Peer avg
P/E	–	81.0
Revenue Growth	+23.2%	+1304.5%
ROE	-29.6%	24.9%

Twist Bioscience Corporation

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison